According to a recently published, industry-sponsored study conducted on 12,852 young women, HPV vaccination was found to reduce HPV-16 infections a mere 0.6% in vaccinated women versus unvaccinated women. At the same time, other high-risk (carcinogenic) HPV infections were diagnosed in vaccinated women 2.6% to 6.2% more frequently than in the unvaccinated women. The increased rate of infections caused by carcinogenic HPV types other than those targeted by Gardasil® in vaccinated women is 4 to 10 times higher than the reduction in HPV 16/18 infections.[1]
These statistics are not exactly encouraging when it comes to demonstrating efficacy for Gardasil®. In fact, quite the opposite – these figures seem to indicate that women who receive Gardasil® may indeed increase their risk of developing cervical cancer from high-risk HPV types that are not targeted by the vaccine.
Medical consumers cannot afford to take the chance of increasing their risk of contracting a disease that has been virtually eradicated by good gynecological care in the United States (cervical cancer) by taking a series of HPV vaccines and hoping they will find out decades later the vaccine worked. It is certainly not a risk children should have to take.
Thursday, February 2, 2012
SaneVax Writes Open Letter to Kathleen Sebelius, Secretary of Health: Rescind approval of Gardasil® due to lack of efficacy during post-licensure monitoring
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment